IL1B and periodontitis: In this study, we found that MCC950 reduced macrophage pyroptosis, suppressed IL-1β secretion, and ameliorated alveolar bone loss, suggesting that targeting inflammasome-mediated inflammation is a novel therapeutic strategy for the treatment of diabetes–periodontitis.